Dr. Anantha Harijith MD

Dr. Anantha K. Harijith is an Associate Professor of Pediatrics at the University of Arizona College of Medicine and a neonatology researcher at University Hospitals Cleveland. His research focuses on neonatal lung diseases, bronchopulmonary dysplasia, asthma, and sepsis-related inflammation. With extensive training in neonatology and clinical pediatrics, Dr. Harijith has contributed to translational studies investigating cellular mechanisms of neonatal respiratory disorders, sphingolipid signaling pathways, and mitochondrial dysfunction in critical illness. He collaborates on both clinical and pre-clinical studies aimed at improving outcomes in premature infants and children with chronic lung disease, publishing widely in respected peer-reviewed journals.

Education details:

• M.D., Medical Degree (Institution not specified in sources)
• MRCP (UK) – Royal College of Physicians, United Kingdom

Professional background:

• Associate Professor of Pediatrics, University of Arizona College of Medicine
• Faculty, Division of Neonatology, University Hospitals Cleveland Medical Center
• Research focus on neonatal lung injury, inflammation, and respiratory biology

Achievements:

• Authored 50+ peer-reviewed publications in neonatology and pediatric lung biology
• Recognized for translational research on bronchopulmonary dysplasia (BPD)
• Active member in pediatric and neonatal research consortia

Current research projects:

• Mechanisms of bronchopulmonary dysplasia in premature infants
• Sphingolipid and lysophosphatidic acid signaling in neonatal lung injury
• Mitochondrial dysfunction and immune dysregulation in neonatal sepsis
• Therapeutic targets in neonatal airway remodeling and inflammation

Dr. Harijith’s recent publications (2024–2025) focus on neonatal lung diseases, mitochondrial dysfunction, and inflammation in critical illness. His work highlights mechanisms underlying bronchopulmonary dysplasia, airway remodeling, and neonatal sepsis.

Recent Publications

1. Sudhadevi T, Harijith A. Mitochondrial dysfunction in febrile illness and sepsis: no clear picture yet. Journal pending. Nov 2024.
2. Ha AW, Sudhadevi T, Jafri A, Harijith A. Bronchopulmonary dysplasia demonstrates dysregulated autotaxin/lysophosphatidic acid signaling in a neonatal mouse model. Oct 2024.
3. Sudhadevi T, Annadi A, Basa P, Harijith A. Fingolimod, a Sphingosine-1-Phosphate receptor modulator prevents neonatal bronchopulmonary dysplasia and subsequent airway remodeling in a murine model. Sep 2024.
4. Sudhadevi T, Harijith A. Thioredoxin: an antioxidant, a therapeutic target and a possible biomarker. Jun 2024.
5. Harijith A, Raffay T, Ryan RM. Postnatal corticosteroid therapy in bronchopulmonary dysplasia – why animal studies disagree with clinical trials? Jun 2024.

Last Updated on October 12, 2025